Skip to content

Ayurvedic trail for treatment of Diabetes mellitus.

A comparative randomized clinical study to evaluate the efficacy of Nitya Virechana with Trivrita kwatha and Aaragvadha Kwatha in the management of Madhumeha (Diabetes mellitus II) - NILL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/05/066990
Enrollment
56
Registered
2024-05-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Sponsors

Ch. Brahm Prakash Ayurved Charak Sansthan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Newly diagnosed patients of Diabetes mellitus type-2 2.Patient fit for virechan 3.Patient who is taking or not taking medicines. 4.Patient whose blood sugar level comes in range as follows- FBS - 120-180mg/dl, PPBS- 150-250mg/dl

Exclusion criteria

Exclusion criteria: 1.Insulin dependent diabetes mellitus or those who are under insulin therapy. 2.Patients with chronic diabetic complications like nephropathy, neuropathy and retinopathy. 3.Patients with severe systemic diseases like HIV, Cancer, Hepatitis etc. 4.Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
Nitya Virechana Karma with Trivrita Kwatha may show better results on maintaining the blood glucoselevel in comparison to Nitya Virechana with Aragvadha Kwatha.Timepoint: 0,1,14,21,42th day

Secondary

MeasureTime frame
Nitya Virechana Karma with Trivrita Kwatha may show better results on maintaining the blood glucose level in comparison to Nitya Virechana with Aragvadha KwathaTimepoint: 21 day

Countries

India

Contacts

Public ContactDr Pankaj Kumar Katara

Ch. Brahm Prakash Ayurved Charak Sansthan

pankaj_katara@yahoo.co.in9910430500

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026